Unibest

Pharmaceutical intermediates

Lutetium (177Lu) vipivotide tetraxetan Intermediates

1 pharmaceutical intermediate for Lutetium (177Lu) vipivotide tetraxetan. Indication: Androgen-independent prostate tumor; Prostate cancer.

Submit a ProjectAll intermediates

About Lutetium (177Lu) vipivotide tetraxetan

Originator
Radiomedix Inc
Indication
Androgen-independent prostate tumor; Prostate cancer
Approved Date
03/23/2022
NCE Patent
03/23/2027
DS/DP
08/15/2028

Available intermediates

1 intermediate currently listed for Lutetium (177Lu) vipivotide tetraxetan. Request specifications, documentation or a quotation for any item below.

Lutetium (177Lu) vipivotide tetraxetan intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 1,4,7-tris(1,1-dimethylethyl) ester, sodium salt (1:1)2583711-51-5//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Lutetium (177Lu) vipivotide tetraxetan?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →